- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 13-10-2025: Press Release
13-10-2025 | 02:49 pm
13-10-2025 | 02:49 pm
Lupin will present Phase 1 data for its LNP3693 STING agonist at the ESMO Congress. The investigational drug targets advanced solid tumors and lymphoma, showcasing safety and preliminary anti-tumor activity.
No comments yet. Be the first to comment!